213 related articles for article (PubMed ID: 15718164)
1. Predictive in silico modeling for hERG channel blockers.
Aronov AM
Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
[TBL] [Abstract][Full Text] [Related]
2. Tuning out of hERG.
Aronov AM
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):128-40. PubMed ID: 18175275
[TBL] [Abstract][Full Text] [Related]
3. Ligand structural aspects of hERG channel blockade.
Aronov AM
Curr Top Med Chem; 2008; 8(13):1113-27. PubMed ID: 18782007
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
6. Predictive models for hERG potassium channel blockers.
Cianchetta G; Li Y; Kang J; Rampe D; Fravolini A; Cruciani G; Vaz RJ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3637-42. PubMed ID: 15978804
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
Choi SY; Koh YS; Jo SH
J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
[TBL] [Abstract][Full Text] [Related]
8. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
9. Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques.
Garg D; Gandhi T; Gopi Mohan C
J Mol Graph Model; 2008 Feb; 26(6):966-76. PubMed ID: 17928249
[TBL] [Abstract][Full Text] [Related]
10. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
11. Building predictive ADMET models for early decisions in drug discovery.
Penzotti JE; Landrum GA; Putta S
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):49-61. PubMed ID: 14982148
[TBL] [Abstract][Full Text] [Related]
12. A binary QSAR model for classification of hERG potassium channel blockers.
Thai KM; Ecker GF
Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
[TBL] [Abstract][Full Text] [Related]
13. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
[TBL] [Abstract][Full Text] [Related]
14. A composite model for HERG blockade.
Kramer C; Beck B; Kriegl JM; Clark T
ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
16. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
17. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
[TBL] [Abstract][Full Text] [Related]
18. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Ermondi G; Visentin S; Caron G
Eur J Med Chem; 2009 May; 44(5):1926-32. PubMed ID: 19110341
[TBL] [Abstract][Full Text] [Related]
19. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
20. Prediction of hERG potassium channel affinity by the CODESSA approach.
Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
